JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Penkov, K.; Haanen, J. B. A. G.; Rini, B. I.; Albiges, L.; Campbell, M. T.; Kollmannsberger, C. K.; Negrier, S.; Uemura, M.; Lee, J. L.; Gurney, H.; Berger, R.; Schmidinger, M.; Larkin, J.; Atkins, M. B.; Wang, J.; Robbins, P. B.; Chudnovsky, A.; Di Pietro, A.; Choueiri, T. K. |
| Abstract Title: | JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy424.036 |
| Language: | English |
| ACCESSION: | WOS:000459277305008 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy424.036 |
| Notes: | Meeting Abstract: LBA6_PR -- Appears on page viii724 of the abstract book -- Source: Wos |
